Previous close | 0.8000 |
Open | 0.4500 |
Bid | 0.0000 |
Ask | 1.5000 |
Strike | 175.00 |
Expiry date | 2024-05-17 |
Day's range | 0.4500 - 0.8000 |
Contract range | N/A |
Volume | |
Open interest | 71 |
BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.
Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.